Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers revisit old trial data to see who benefits most from immunotherapy

NCT ID NCT07478809

Recruiting now Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 01, 2026 · Updated 9 times

Summary

This study is collecting long-term survival information from 109 people with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand the lasting benefits of this immunotherapy and identify which patients gain the most advantage. No new treatments are being given; it is a retrospective analysis of existing data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)